The use of unit root and Box-Jenkins in Amman Stock Exchange (ASE)

This paper aims at examining the level of the efficiency of Amman Stock Exchange (ASE) on weak form, semi-strong form and strong form levels from January 2008 to December 2014. The paper concludes that there is a significant prediction performance of all ASE indices of the Jordanian market by using Box-Jenkins estimation. This result was confirmed by unit-root test since the return series for the five Jordanian indices failed to prove unit root

Thermal enhancement and numerical solution of blood nanofluid flow through stenotic artery

The blood flow through stenotic artery is one of the important research area in computational fluid mechanics due to its application in biomedicine. Aim of this research work is to investigate the impact of nanoparticles on the characteristics of human blood flow in a stenosed blood artery. In under consideration problem Newtonian fluid is assumed as human blood. Newtonian fluid flows through large blood vessels (more than 300 mu m). The constitutive equations together with the boundary conditions are diminished to non-dimensional form by using boundary layer approximation and similarity transfiguration to attain the solution of velocity and temperature distribution of blood flow through arterial stenosis numerically with the help of Matlab bvp4c. The results for physical quantities at cylindrical surface are calculated and their effects are also presented through tables. The heat transfer rate increases throughout the stenosed artery with the concentration of copper nanoparticle. Velocity curve decreases by increasing the values of flow parameter and nanoparticle volume fraction. Temperature curve increases due to increase in the values of nanoparticle volume fraction and decrease in Prandtl number.The work of U.F.-G. was supported by the government of the Basque Country for the ELKA-RTEK21/10 KK-2021/00014 and ELKARTEK22/85 research programs, respectively. Additionally, this work was supported by the Researchers Supporting Project Number (RSP-2021/33), King Saud University, Riyadh, Saudi Arabia

Heat transport investigation of engine oil based rotating nanomaterial liquid flow in the existence of partial slip effect

In this study, rotational nano liquid movement above a linearly stretching surface has been formulated. A two-phase model is used for this analysis. Base fluid engine oil and two distinct types of nanoparticles are used as nanoparticles, i.e. copper and aluminum oxide (Cu & Al2O3). This study is aimed to describe the changed possessions on velocity and temperature for rotational nanofluid flow above a linear enlarging surface in the existence of the slip effect. The leading structure of PDEs is converted into ODEs with a similarity transformation. Numerical findings are gained utilizing a sophisticated numerical approach. For both nanofluids, the results for rotational flow and heat transmission characteristics are emphasized with the help of graphs. At the linear extending surface, the influence of physical concentrations like heat flow rates and skin friction coefficients is investigated and visually clarified. Cunanoparticles proved to be better heat carriers than Al2O3 nanoparticles

Heat and mass transfer analysis of nonlinear mixed convective hybrid nanofluid flow with multiple slip boundary conditions

The current study focuses on the 3D nonlinear mixed convective boundary layer flow of micropolar hybrid nanofluid in the presence microorganism and multiple slip conditions across the slendering surface. The concentration and energy equations are developed in the occurrence of activation energy and joule heating effect. The aim of this research is to consider the Carbon nanotubes (CNTs) which are favored materials in the manufacture of electrochemical devices because of their mechanical and chemical stability, good thermal and electrical conductivities, physiochemical consistency, and featherweight. By keeping such extraordinary properties of carbon nanotubes in mind, we investigate the flow of hybrid nanofluid having MWCNT (multi-wall carbon nanotubes) and SWCNT (single-wall carbon nanotubes). Using an appropriate similarity variable, the flow model (PDEs) are converted into nonlinear ordinary differential equations. The bvp4c approach is utilized to tackle the coupled differential equations. The impact of emerging parameter on temperature distribution, velocity field, concentration distribution, and microorganism field are presented graphically. It is noted the stronger values of wall thickness parameter and Hartmann number produces retardation effect, as a result fluid velocity declines for both SWCNT (single-wall carbon nanotubes) and MWCNT (multi-wall carbon nanotubes) hybrid nanofluid. Furthermore, the transport rate of heat and mass improves by the higher values of for φ2 both simple and hybrid nanofluid.</p

Spectrum of antihypertensive therapy in South Asians at a tertiary care hospital in Pakistan

<p>Abstract</p> <p>Background</p> <p>Despite available guidelines on hypertension (HTN), use of antihypertensives is variable. This study was designed to ascertain frequency of patients on monotherapy and > 1 antihypertensive therapy and also to ascertain proportion of patients on diuretic therapy.</p> <p>Methods</p> <p>It was a crossectional study conducted on 1191 adults(age > 18 yrs)hypertensive patients selected by computerized International Classification of Diseases -9-coordination and maintenance (ICD-9-CM) presenting to a tertiary care hospital in Pakistan. Data on demographics, comorbids, type of antihypertensive drug, number of antihypertensive drug and mean duration of antihypertensive drug was recorded over 1.5 year period (2008-09). Blood pressure was recorded on admission. Primary outcome was use of combination therapy and secondary outcome was use of diuretic therapy.</p> <p>Results</p> <p>A total of 1191 participants were included. Mean age(SD) was 62.55(12.47) years, 45.3%(540) were males. Diabetes was the most common comorbid; 46.3%(551). Approximately 85% of patients had controlled hypertension. On categorization of anti hypertensive use into 3 categories;41.2%(491) were on monotherapy,32.2%(384) were on 2 drug therapy,26.5%(316) were on ≥3 drug therapy. Among those who were on monotherapy for HTN;34%(167) were on calcium channel blockers,30.10%(148) were on beta blockers, 22.80%(112) were on Angiotensin converting enzyme (ACE) inhibitors,12%(59) were on diuretics and 2.20%(11) were on Angiotensin receptor blockers(ARB). Use of combination antihypertensive therapy was significantly high in patients with ischemic heart disease(IHD)(p < 0.001). Use of diuretics was in 31% (369) patients. Use of diuretics was significantly less in patients with comorbids of diabetes (p 0.02), Chronic kidney disease(CKD)(p 0.003), IHD (p 0.001) respectively</p> <p>Conclusion</p> <p>Most patients presenting to our tertiary care center were on combination therapy. Calcium channel blocker is the most common anti hypertensive drug used as monotherapy and betablockers are used as the most common antihypertensive in combination. Only a third of patients were on diuretic as an antihypertensive therapy.</p

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p&lt;0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p&lt;0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark